Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group. Kalincik T, et al. Among authors: lugaresi a. Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11. Lancet Neurol. 2017. PMID: 28209331 Free article.
Apolipoprotein E genotype does not influence the progression of multiple sclerosis.
Savettieri G, Andreoli V, Bonavita S, Cittadella R, Caltagirone C, Fazio MC, Girlanda P, Le Pira F, Liguori M, Logroscino G, Lugaresi A, Nocentini U, Reggio A, Salemi G, Serra P, Tedeschi G, Toma L, Trojano M, Valentino P, Quattrone A. Savettieri G, et al. Among authors: lugaresi a. J Neurol. 2003 Sep;250(9):1094-8. doi: 10.1007/s00415-003-0163-8. J Neurol. 2003. PMID: 14504972
Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis.
Savettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, Farina D, Fazio MC, Girlanda P, Le Pira F, Liguori M, Lugaresi A, Nocentini U, Reggio A, Salemi G, Tedeschi G, Trojano M, Valentino P, Quattrone A. Savettieri G, et al. Among authors: lugaresi a. J Neurol. 2004 Oct;251(10):1208-14. doi: 10.1007/s00415-004-0508-y. J Neurol. 2004. PMID: 15503099
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group. Patti F, et al. Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544. Mult Scler. 2009. PMID: 19542262
Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Patti F, et al. Mult Scler. 2010 Jan;16(1):68-77. doi: 10.1177/1352458509350309. Epub 2009 Dec 7. Mult Scler. 2010. PMID: 19995846 Clinical Trial.
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
Devonshire V, Arbizu T, Borre B, Lang M, Lugaresi A, Singer B, Verdun di Cantogno E, Cornelisse P. Devonshire V, et al. Among authors: lugaresi a. BMC Neurol. 2010 Apr 30;10:28. doi: 10.1186/1471-2377-10-28. BMC Neurol. 2010. PMID: 20433746 Free PMC article. Clinical Trial.
Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group. Patti F, et al. Mult Scler. 2011 Aug;17(8):991-1001. doi: 10.1177/1352458511401943. Epub 2011 Apr 18. Mult Scler. 2011. PMID: 21502310 Clinical Trial.
Anxiety and depression in multiple sclerosis patients around diagnosis.
Giordano A, Granella F, Lugaresi A, Martinelli V, Trojano M, Confalonieri P, Radice D, Solari A; SIMS-Trial group. Giordano A, et al. Among authors: lugaresi a. J Neurol Sci. 2011 Aug 15;307(1-2):86-91. doi: 10.1016/j.jns.2011.05.008. Epub 2011 May 31. J Neurol Sci. 2011. PMID: 21621796 Clinical Trial.
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.
Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group. Hughes S, et al. Among authors: lugaresi a. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28. J Neurol Neurosurg Psychiatry. 2012. PMID: 22205675
281 results